Home
overview

The SMi Group is delighted to announce its 20th Annual Pain Therapeutics conference held in London on the 11th and 12th May 2020.

The Global Pain Therapeutics Market was valued at $11.26 Million in 2018 and is projected to reach $15.87 Million by 2026, growing at a CAGR of 4.40 % from 2019 to 2026. Improving pain management continues to be a priory as pain-derived disabilities such as osteoarthritis, back pain, migraines and cancer are leading cause of disability worldwide. Yet, pain treatment remains the biggest clinical burden of the age as a result of lack of efficacy, increasing side effects and the opioid crisis that is now entering Europe following its epidemic in the USA.

The 20th Annual Conference will overview the current state of pain treatment highlighting clinical success to date as well as evaluating the potential of drug candidates in the pipelines.

Join Europe's leading Pain Therapeutics Conference which will explore the cutting-edge research of novel therapeutics in the pipeline of leading pharmaceutical companies and research institutions. Discuss solutions for the challenges of understanding pain as a heterogenous disease and the diverse treatment approaches it requires.

• Network with leading pharmaceutical companies and academic researchers of the pain community including GSK, Centrexion, Grunenthal Group, Mundipharma Research Limited, UCL, Janssen, University of Edinburgh and many more!

• Rethink pain research by exploring novel biomarkers, sex differences in nociception, pain clinical trial design and novel targets

• Learn about the struggles of opioid-based treatments and explore the current stages of clinical research with non-opioid targets such as; cannabinoid receptor 2, nociception/orphanin FQ peptide (NOP) receptor, ENKephalinase and NGF receptors

• Improve your understanding of neuro-immune interactions and their role in pain pathology, a promising new angle of pain research
 

Adynxx Inc.; Alterion Consulting; Asahi Kasei Pharma; Asahi Kasei Pharma Corporation; AstraZeneca; AstraZeneca R&D Biopharmaceuticals; Bayer AG; BRAINCURES LTD; Centre for Human Drug Research; Centrexion Therapeutics Corp; Clexio Biosciences; Domain Therapeutics ; Eli Lilly and Company; Ensysce Biosciences Inc.; Grunenthal; Grünenthal GmbH; Grunenthal Group; Grunenthal Ltd; GSK; Janssen Pharmaceutica N.V.; Levicept; Lotus Clinical Research, LLC; MD Biosciences; Medherant Limited; Metys Pharmaceuticals Ltd; Pfizer Ltd; Pharmaleads; Reckitt Benckiser; Tools4patient; Travecta Therapeutics; UMR 1107 INSERM/UCA NEURO-DOL; Vertex Pharmaceuticals; ViroMed ;

Conference programme

8:30 Registration & Coffee

9:00 Chairs' Opening Remarks

Kerrie Brady

Kerrie Brady, Chief Business Officer, Centrexion Therapeutics Corp
View Bio

Michael Scherz

Michael Scherz, Founder & CEO, Metys Pharmaceuticals Ltd
View Bio

9:10 Facilitating Pain Research via Biomarker Discovery

Richard Malamut

Richard Malamut, Chief Medical Officer and SVP R&D, Collegium Pharma
View Bio

•Evaluating the role of biomarkers in pain research
•Identifying biomarkers – where are we now?
•Establishing biomarkers in patient populations
•Highlighting the importance of biomarker discovery and its contribution to early stage studies on pain

9:50 Bridging the translational gap in analgesic drug development

Zahid Ali

Zahid Ali, Head Clinical Pharmacology Translational Sciences, Mundipharma research Ltd
View Bio

•What have we learnt from over 20 years of concerted analgesic drug development?
•The integration of clinical, non-clinical and disease area knowledge for more effective decision making
•The impact of new technologies on translational approaches in analgesic drug development
•One size does not fit all- developing more targeted and effective analgesics

10:30 Morning Coffee

11:00 Neurotrophins in pain models

Cristina Cosi

Cristina Cosi, Senior Scientist Pharmacology, CNS Innovation Unit, Pierre Fabre Research Institute
View Bio

•Pain models for pre-clinical research
•Focus on BDNF, NGF, TrkB, TrkA systems
•Biomarkers, target validation and engagement
•Considering translatability of pain across species

11:40 Sex Differences in Pain Mechanisms

Carole Torsney

Carole Torsney, Senior Lecturer, University of Edinburgh
View Bio

•Highlight evidence for sex differences in neuro-immune interactions
•Highlight evidence for sex differences in PNS and CNS plasticity
•Discuss sex differences in the temporal relay of pain signals by nociceptors
•Address the need for preclinical research on both sexes to improve translation

12:20 Networking Lunch

13:20 Pain clinical trials - myths and momentum

Kerrie Brady

Kerrie Brady, Chief Business Officer, Centrexion Therapeutics Corp
View Bio

•Examining pain clinical trial myths
•Raising patient awareness to improve clinical trials
•Consideration of new clinical trial design approaches

14:00 Panel Discussion: Novel drug targets on the horizon

•Discussing the diversity of targets that have been explored for the treatment of neuropathic pain
•Evaluating the current situation and status of targets in clinic
•What are the new targets on the horizon that should be fully explored?
•Starting with a target ending with a drug – challenges encountered

Richard Malamut

Richard Malamut, Chief Medical Officer and SVP R&D, Collegium Pharma
View Bio

Sandrine Geranton

Sandrine Geranton, Senior Research Fellow, UCL Institute of Ophthalmology
View Bio

Jennifer Laird

Jennifer Laird, Senior Director, Search & Evaluation at Eli Lilly, Eli Lilly And Company

14:40 Selecting targets for a novel pain therapy: Expanding the druggable space

Jennifer Laird

Jennifer Laird, Senior Director, Search & Evaluation at Eli Lilly, Eli Lilly And Company

•Translatability of preclinical evidence is debated in the pain field, but are there exceptions that prove (or disprove) the rule?
•Alternatively, can we take an opportunistic approach and focus on targets with clinical evidence provided by serendipity?
•This presentation will address those questions and also discuss how novel modalities like oligonucleotides or gene therapy can change the types of targets we focus our efforts on
 

15:20 Afternoon Tea

15:50 FKBP51 and the stress axis: novel targets for the control of chronic pain

Sandrine Geranton

Sandrine Geranton, Senior Research Fellow, UCL Institute of Ophthalmology
View Bio

•Stress and chronic pain are known to exacerbate each
other but the underlying mechanisms remain elusive
•FKBP51 is a well-known regulator of the stress axis and its inhibition improves anxiety-like behaviour in mouse models
•We have shown that FKBP51 is a crucial driver of persistent pain states
•Targeting the stress axis overall is likely to reduce the pain experience

16:30 Evaluation of the Selective Cannabinoid 2 Receptor Agonist CNTX-6016 for the Treatment of Neurophatic pain

James Campbell

James Campbell, Chief Scientific Officer , Centrexion Therapeutics Corp

•Introducing CB2 receptors as targets and their implication in pain
Presenting recent result from clinical trials of CNTX-6016
•Implications for treatment of chronic neuropathic pain, such as diabetic neuropathic pain and chemotherapy induced neuropathy

17:10 What can we Learn from the Opioid Crisis?

Theo Meert

Theo Meert, Head of R&D Global Government Grant Office, Janssen Pharmaceutica N.V.
View Bio

•Addressing the global misuse of opioids and evaluating
new treatment options
•Raising public awareness and taking the society and sociological consequences into account
•Highlighting what action needs to be taken to restrict
opioid overuse
•Discussing lessons learnt and how can these be applied
to avoid a potential “ketamine crisis”?

8:30 Registration & Coffee

9:00 Chairs' Opening Remarks

Kerrie Brady

Kerrie Brady, Chief Business Officer, Centrexion Therapeutics Corp
View Bio

Michael Scherz

Michael Scherz, Founder & CEO, Metys Pharmaceuticals Ltd
View Bio

9:10 The impact of chronic pain – the patient’s perspective

Joop van Griensven

Joop van Griensven, President , Pain Alliance Europe (PAE)
View Bio

•Understanding the effects of chronic pain on the quality of life and on society
•Observing health aspects of chronic pain
•Promoting awareness and helping patient cope with chronic pain

9:50 Revolutionising pain R&D by developing Precision Analgesics

Mark  J Field

Mark J Field, Owner/Founder, Analgesic Innovation

•Overviewing the impact of pain and its huge global burden with up to 1 in 4
•Discussing the pain therapeutics- an area with the LOWEST R&D success rates
•Learning what factors are hindering analgesic development
•Developing precision analgesics can radically improve probability of success

10:30 Morning Coffee

11:00 The role of Neuro-Immune Interactions in Chronic Pain

Edward Emery

Edward Emery, Investigator, GSK
View Bio

•Introducing the concept of interacting neurons and immune cells in the pathophysiology of pain
•Exploring the contributions of the immune system to chronic pain
•Understanding the role of the immune system in pain facilitation
•Overviewing potential strategies for targeting the immune system to treat pain

11:40 Emphasising Disease Understanding to deliver effective pain treatments. Exploring NOP receptor pharmacology as an exciting opportunity to treat neuronal hypersensitivity driven pain disorders

Paul Ratcliffe

Paul Ratcliffe, Vice President, Setup Innovation Hubs , Grunenthal Group
View Bio

•Grunenthal’s approach to tackle the underlying pathophysiologies of pain

•Targeting the nociception/orphanin FQ peptide (NOP) receptor; a journey navigating between the pre-clinic and clinical environment

12:20 Networking Lunch

13:20 Therapeutic efficacy of neurotoxins in pain

14:00 Novel botulinum-based constructs for the long-term control of persistent pain states in mice

Stephen Hunt

Stephen Hunt, Professor, UCL

•The evidence for opiate control of chronic pain states is poor
•This is related to the development of tolerance, increased pain sensitivity and therefore escalating dose of opiate drug that can lead to addiction.
•A novel conjugation of dermorphin to the silencing domain of botulinum toxin, that is safe to produce under laboratory conditions, results in long term amelioration of persistent pain states in mice following one intrathecal injection.
•The analgesia lasts for over three months without killing neurons or obvious toxic events

14:40 Afternoon Tea

15:10 Limitations of Current Migraine Treatment Options: the Patients’ Perspective

Domenico Merante

Domenico Merante, VP Clinical Development, Independent

•Overviewing the current migraine treatment landscape with special focus on the patient
•How do patients respond to available treatment?
•Considering aspects of tolerability and side effects
•Examining efficacy limitations of current treatments

15:50 Recent Progress of PL37 – a Dual ENKephalinase Inhibitor for migraine treatment

Tanja Ouimet

Tanja Ouimet, Head of Clinical Operations, Pharmaleads
View Bio

•Introducing DENKI and PL37 MoA
•Presenting recent preclinical pharmacology results on the potential of PL37 in migraine treatment
•Assessing the potential of PL37 and future studies required

17:00 Chairman’s Closing Remarks and Close of Day Two

+

VENUE

Copthorne Tara Hotel

Scarsdale Place, Kensington, London, United Kingdom

The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

 

A number of our clients have been approached by third party organisations offering to book hotel rooms. We would advise that you do not book through them as they are not representing the SMi Group. SMi Group books all hotel rooms directly. If you are approached by a third party organisation then please contact us before making any bookings. If you have already booked a hotel room using a third party organisation, we would highly recommend contacting the hotel you were booked into to ensure a booking has been made for you. We would also advise you to please check the terms and conditions of the booking carefully.
HOTEL BOOKING FORM

Past Attendees

Download

Pain Therapeutics Conference 2019 - Janssen

Download

Pain Therapeutics Conference 2019 - CHDR

Download

Pain Therapeutics Conference 2019 - Ensysce Biosciences

Download

Pain Therapeutics Conference 2019 - Pfizer

Download

Pain Therapeutics Conference 2019 - Lotus

Download

Pain Therapeutics Conference 2019 - Centrexion

Download

SAVE TO


Outlook Calendar  OUTLOOK CALENDAR
Google Calendar  GOOGLE CALENDAR
ICal Calendar  ICAL CALENDAR
Yahoo! Calendar  YAHOO! CALENDAR

Copthorne Tara Hotel

Scarsdale Place
Kensington
London W8 5SR
United Kingdom

Copthorne Tara Hotel

The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

 

HOTEL BOOKING FORM

Title

SubTitle
speaker image

Content


Title


Description

Download


WHAT IS CPD?

CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

CPD AND PROFESSIONAL INSTITUTES

There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

GLOBAL CPD

Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

CPD Certificates

We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

Event Title

Headline

Text
Read More

I would like to speak at an event

I would like to attend an event

I would like to sponsor/exhibit at an event

SIGN UP OR LOGIN

Sign up
Forgotten Password?

Contact SMi GROUP LTD

UK Office
Opening Hours: 9.00 - 17.30 (local time)
SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
Registered in England No: 3779287 VAT No: GB 976 2951 71




Forgotten Password

Please enter the email address you registered with. We will email you a new password.

Thank you for visiting our event

If you would like to receive further information about our events, please fill out the information below.

By ticking above you are consenting to receive information by email from SMi.
Full details of our privacy policy can be found here https://www.smi-online.co.uk/privacy-legals/privacy-policy/.
Should you wish to update your contact preferences at any time you can contact us at data@smi-online.co.uk.
Should you wish to be removed from any future mailing lists please click on the following link http://www.smi-online.co.uk/opt-out